Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....